Skip to content

Evaluate the efficacy and safety of PartySmart Soft Chews

â??A double-blind, placebo-controlled, comparative clinical study followed by an Open-label extension study, to evaluate the efficacy and safety of PartySmart Soft Chewsâ??

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042617
Enrollment
40
Registered
2022-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and female subjects aged between 20-50 years, weighing more than 45 kgs. 2. Subjects who used to drink alcohol regularly (social drink, but not alcohol abuse) and is willing and able to comply with the alcohol consumption, blood withdrawal requirements and overnight stay as per the study requirements. 3. Subjects judged by the Investigator to be in general good health based on medical history. 4. Subjects understand the study procedures and sign the informed consent forms to participate in the study

Exclusion criteria

Exclusion criteria: 1 Subjects suspected for drug or alcohol abuse. 2. A medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation. 3. Subjective sleep duration of less than 3 hours in the night before every study period. 4. Caffeine, nicotine on the day (from midnight) of the every study Period. 5. Alcohol consumption within 7 days of enrollment in the study 6. Use of psycho-active drugs during the past 30 days or any treatment that might interfere with the evaluation of the test drug. 7. Subjects taking any drug known to interact with benzodiazepines and other drugs, e.g. antiepileptics, antihistamines, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450. 8. Subjects suffering from any clinically significant disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, neurological and or psychiatric disorder etc.). 9. Known hypersensitivity to any of the ingredients of the study drugs. 10. Participation in any other clinical trial within the past 30 days.

Design outcomes

Primary

MeasureTime frame
1.Change in the blood alcohol and acetaldehyde levels 2.Clinical symptoms related to alcohol consumption 3. Assessment of Alcohol Hangover Questionnaire (AHQ)Timepoint: 12 Hours

Secondary

MeasureTime frame
Incidence of adverse effects.Timepoint: 12 Hours

Countries

India

Contacts

Public ContactSuresh Kumar V S

Himalaya Wellness Company

dr.srikrishna@himalayawellness.com08067547230

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026